Novo Nordisk’s Alzheimer’s Trials Show No Significant Progress

An update from Novo Nordisk ( (NVO) ) is now available.

On November 24, 2025, Novo Nordisk announced the results of its evoke and evoke+ phase 3 trials, which aimed to evaluate the efficacy of semaglutide in slowing Alzheimer’s disease progression. The trials, involving 3,808 adults, did not show a statistically significant reduction in disease progression compared to placebo. Despite improvements in Alzheimer’s-related biomarkers, semaglutide did not delay disease progression, leading to the discontinuation of the trials’ extension period. Novo Nordisk will present these findings at upcoming conferences, highlighting the continued need for effective Alzheimer’s treatments.

The most recent analyst rating on (NVO) stock is a Hold with a $50.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.

Spark’s Take on NVO Stock

According to Spark, TipRanks’ AI Analyst, NVO is a Outperform.

Novo Nordisk’s strong financial performance and reasonable valuation are key strengths, supporting a solid overall score. However, bearish technical indicators and challenges highlighted in the earnings call, such as market share loss and restructuring, weigh on the score. The company’s strategic focus on long-term growth and attractive dividend yield provide additional support.

To see Spark’s full report on NVO stock, click here.

More about Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. The company focuses on defeating serious chronic diseases, particularly diabetes, through pioneering scientific breakthroughs and expanding access to medicines. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries.

Average Trading Volume: 15,143,512

Technical Sentiment Signal: Sell

Current Market Cap: $208.4B

For an in-depth examination of NVO stock, go to TipRanks’ Overview page.